XNAS · NBIX
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Neurocrine Biosciences Inc

Neurocrine Biosciences Inc

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$154.49
Card
Relationship Map

Veridion Score

BETAHIGH CONF · 6/6 factorsMethodology
NBIX
Neurocrine Biosciences Inc
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
BUY BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

63/ 100
Veridion Score
BUY BIAS · HIGH confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Score not reportedVeridion does not publish a score-history trend for NBIX until the ticker has a real scored snapshot. No trend is implied for this page.Review methodology
AI Analysis
Sovereign

Why is NBIX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NBIX catalysts
About Neurocrine Biosciences Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
1996
Employees
3K
Country
US

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$154.49
Last session
Day high
$154.49
Last session
Day low
$154.49
Last session
Previous close
$154.49
52W high
$185.50
-16.72% from high
52W low
$123.10
50% of range
Market cap
$15.5B
P/E
24.14×
EPS
$6.40
Beta
0.38
Shares out
101.6M
Avg volume
1.3M
VWAP
$154.49
Last session
Price history computed in-house
1W
-4.60%
1M
-9.59%
3M
-0.12%
1Y
+16.04%
YTD
+8.93%
SMA 50 $167.69 · below
SMA 200 $146.89 · above
52W position 50%

NBIX overview

Veridion Score
Not reported
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NBIX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NBIX Form 4 filings
Public disclosures

Congress activity in NBIX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NBIX in the cached public ledger.

Federal contracts

NBIX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NBIX in this window.
Lobbying spend

NBIX lobbying filings, year to date.

Registered lobbying filings matched to Neurocrine Biosciences Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NBIX in this window.
Loading news for NBIX
Analyst ratings
Sovereign unlock shows live analyst consensus for NBIX.
Options
Sovereign unlock shows live options positioning for NBIX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.